What is ProJenX?
ProJenX is pioneering the development of patient-specific, cell-based drug discovery platforms aimed at addressing complex neurodegenerative conditions. The company's initial focus is on ALS, a devastating neurological disorder. Its approach is rooted in breakthroughs from a long-term research collaboration between Project ALS and Columbia University, which yielded critical insights into motor neuron degeneration and the creation of the first ALS patient-derived disease models. This foundation allows ProJenX to explore novel therapeutic avenues for conditions with significant unmet medical needs.
How much funding has ProJenX raised?
ProJenX has raised a total of $15M across 1 funding round:
Series A
$15M
Series A (2023): $15M with participation from Medical Excellence Capital
Key Investors in ProJenX
Medical Excellence Capital
Medical Excellence Capital (MEC) is an early-stage life sciences venture fund focused on advancing precision health innovations through precision capital. The firm combines experienced investment professionals with a proprietary national medical network to address complex medical challenges. MEC invests in transformative technologies and novel approaches that meet significant unmet needs in patient care, targeting company creation and early funding stages.
What's next for ProJenX?
With this substantial backing, ProJenX is poised to accelerate its research and development pipeline, potentially moving its targeted therapies closer to clinical trials. The strategic investment will likely fuel further expansion of its proprietary cell-based discovery platform and deepen its understanding of neurodegenerative disease mechanisms. Future endeavors may include forging new strategic partnerships, expanding its scientific advisory board, and advancing its lead drug candidates through rigorous preclinical and clinical testing, aiming to bring innovative treatments to patients suffering from ALS and other neurodegenerative disorders.
See full ProJenX company page
